FPMAJ Urges Caution with Market Expansion Re-Pricing, Says Add’l Indications Now Seen as Price Cut Risk

The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) on June 11 urged regulators to clarify criteria for market expansion re-pricing and make careful decisions in applying the rule, noting that pharma companies now see that additional indications come with...read more